Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings ...

JAK1 inhibitors showed superior antipruritic effects compared to IL-13 antibodies in atopic dermatitis treatment within three months. TARC levels indicated potential benefits of IL-13 antibodies, ...

Atopic dermatitis (AD) takes a significant emotional and physical toll, with flare-ups often measured using subjective scoring methods. The new SCCA2 assay offers a way to shift toward more objective, ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating nemolizumab in atopic dermatitis and ...

Please provide your email address to receive an email when new articles are posted on . Significant improvement in IGA and EASI scores were found in patients treated with amlitelimab vs. placebo. Many ...

Newborns who go on to develop atopic dermatitis (AD) show higher transepidermal water loss (TEWL) and cord blood serum levels of CCL17/thymus- and activation-regulated chemokine (TARC) and interleukin ...

New research identifies a specific neural pathway (Pdyn+ neurons) that carries stress signals from the brain to the skin, triggering eczema flares by activating eosinophils.

Kymera Therapeutics (NASDAQ:KYMR) used its fourth-quarter 2025 update call to highlight what management described as a “breakout year” driven by clinical progress for its oral STAT6 degrader KT-621, ...

DENVER - A new study conducted by researchers at National Jewish Health has found that early changes in the cheek skin barrier may predict the onset of eczema, or atopic dermatitis (AD), well before ...

In A Nutshell Researchers used computer modeling and physics-based math to calculate the minimum antibiotic and moisturizer doses needed to push severe eczema into remission and keep it there. The ...